200 results on '"Young Hee Nam"'
Search Results
2. Patient characteristics, pain treatment patterns, and incidence of total joint replacement in a US population with osteoarthritis
- Author
-
Mayura Shinde, Carla Rodriguez-Watson, Tancy C. Zhang, David S. Carrell, Aaron B. Mendelsohn, Young Hee Nam, Amanda Carruth, Kenneth R. Petronis, Cheryl N. McMahill-Walraven, Aziza Jamal-Allial, Vinit Nair, Pamala A. Pawloski, Anne Hickman, Mark T. Brown, Jennie Francis, Ken Hornbuckle, Jeffrey S. Brown, and Jingping Mo
- Subjects
Administrative claims data ,Osteoarthritis ,Pain medications ,Total joint replacement ,Treatment patterns ,US FDA Sentinel Distributed Database ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Background Currently available medications for chronic osteoarthritis pain are only moderately effective, and their use is limited in many patients because of serious adverse effects and contraindications. The primary surgical option for osteoarthritis is total joint replacement (TJR). The objectives of this study were to describe the treatment history of patients with osteoarthritis receiving prescription pain medications and/or intra-articular corticosteroid injections, and to estimate the incidence of TJR in these patients. Methods This retrospective, multicenter, cohort study utilized health plan administrative claims data (January 1, 2013, through December 31, 2019) of adult patients with osteoarthritis in the Innovation in Medical Evidence Development and Surveillance Distributed Database, a subset of the US FDA Sentinel Distributed Database. Patients were analyzed in two cohorts: those with prevalent use of “any pain medication” (prescription non-steroidal anti-inflammatory drugs [NSAIDs], opioids, and/or intra-articular corticosteroid injections) using only the first qualifying dispensing (index date); and those with prevalent use of “each specific pain medication class” with all qualifying treatment episodes identified. Results Among 1 992 670 prevalent users of “any pain medication”, pain medications prescribed on the index date were NSAIDs (596 624 [29.9%] patients), opioids (1 161 806 [58.3%]), and intra-articular corticosteroids (323 459 [16.2%]). Further, 92 026 patients received multiple pain medications on the index date, including 71 632 (3.6%) receiving both NSAIDs and opioids. Altogether, 20.6% of patients used an NSAID at any time following an opioid index dispensing and 17.2% used an opioid following an NSAID index dispensing. The TJR incidence rates per 100 person-years (95% confidence interval [CI]) were 3.21 (95% CI: 3.20–3.23) in the “any pain medication” user cohort, and among those receiving “each specific pain medication class” were NSAIDs, 4.63 (95% CI: 4.58–4.67); opioids, 7.45 (95% CI: 7.40–7.49); and intra-articular corticosteroids, 8.05 (95% CI: 7.97–8.13). Conclusions In patients treated with prescription medications for osteoarthritis pain, opioids were more commonly prescribed at index than NSAIDs and intra-articular corticosteroid injections. Of the pain medication classes examined, the incidence of TJR was highest in patients receiving intra-articular corticosteroids and lowest in patients receiving NSAIDs.
- Published
- 2022
- Full Text
- View/download PDF
3. Using the IMEDS distributed database for epidemiological studies in type 2 diabetes mellitus
- Author
-
Young Hee Nam, Tongtong Wang, Robert T Greenlee, James Marshall, Aaron B Mendelsohn, Aziza Jamal-Allial, Sengwee Toh, Ting-Ying Huang, Carla Rodriguez-Watson, Shawna R Calhoun, Jillian Burk, Mano Selvan, Pamala A Pawloski, Cheryl N McMahill Walraven, Ashish Rai, and Jeffery S Brown
- Subjects
Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Introduction This study aimed to assess data relevancy and data quality of the Innovation in Medical Evidence Development and Surveillance System Distributed Database (IMEDS-DD) for diabetes research and to evaluate comparability of its type 2 diabetes cohort to the general type 2 diabetes population.Research design and methods A retrospective study was conducted using the IMEDS-DD. Eligible members were adults with a medical encounter between April 1, 2018 and March 31, 2019 (index period). Type 2 diabetes and co-existing conditions were determined using all data available from April 1, 2016 to the most recent encounter within the index period. Type 2 diabetes patient characteristics, comorbidities and hemoglobin A1c (HbA1c) values were summarized and compared with those reported in national benchmarks and literature.Results Type 2 diabetes prevalence was 12.6% in the IMEDS-DD. Of 4 14 672 patients with type 2 diabetes, 52.8% were male, and the mean age was 65.0 (SD 13.3) years. Common comorbidities included hypertension (84.5%), hyperlipidemia (82.8%), obesity (45.3%), and cardiovascular disease (44.7%). Moderate-to-severe chronic kidney disease was observed in 20.2% patients. The most commonly used antihyperglycemic agents included metformin (35.7%), sulfonylureas (14.8%), and insulin (9.9%). Less than one-half (48.9%) had an HbA1c value recorded. These findings demonstrated the notable similarity in patient characteristics between type 2 diabetes populations identified within the IMEDS-DD and other large databases.Conclusions Despite the limitations related to HbA1c data, our findings indicate that the IMEDS-DD contains robust information on key data elements to conduct pharmacoepidemiological studies in diabetes, including member demographic and clinical characteristics and health services utilization.
- Published
- 2022
- Full Text
- View/download PDF
4. Healthcare claims-based Lyme disease case-finding algorithms in the United States: A systematic literature review.
- Author
-
Young Hee Nam, Sarah J Willis, Aaron B Mendelsohn, Susan Forrow, Bradford D Gessner, James H Stark, Jeffrey S Brown, and Sarah Pugh
- Subjects
Medicine ,Science - Abstract
Background and objectiveLyme disease (LD) is the fifth most commonly reported notifiable infectious disease in the United States (US) with approximately 35,000 cases reported in 2019 via public health surveillance. However, healthcare claims-based studies estimate that the number of LD cases is >10 times larger than reported through surveillance. To assess the burden of LD using healthcare claims data and the effectiveness of interventions for LD prevention and treatment, it is important to use validated well-performing LD case-finding algorithms ("LD algorithms"). We conducted a systematic literature review to identify LD algorithms used with US healthcare claims data and their validation status.MethodsWe searched PubMed and Embase for articles published in English since January 1, 2000 (search date: February 20, 2021), using the following search terms: (1) "Lyme disease"; and (2) "claim*" or "administrative* data"; and (3) "United States" or "the US*". We then reviewed the titles, abstracts, full texts, and bibliographies of the articles to select eligible articles, i.e., those describing LD algorithms used with US healthcare claims data.ResultsWe identified 15 eligible articles. Of these, seven studies used LD algorithms with LD diagnosis codes only, four studies used LD diagnosis codes and antibiotic dispensing records, and the remaining four studies used serologic test order codes in combination with LD diagnosis codes and antibiotics records. Only one of the studies that provided data on algorithm performance: sensitivity 50% and positive predictive value 5%, and this was based on Lyme disease diagnosis code only.ConclusionsUS claims-based LD case-finding algorithms have used diverse strategies. Only one algorithm was validated, and its performance was poor. Further studies are warranted to assess performance for different algorithm designs and inform efforts to better assess the true burden of LD.
- Published
- 2022
- Full Text
- View/download PDF
5. Utilization patterns and characteristics of users of biologic anti‐inflammatory agents in a large, US commercially insured population
- Author
-
Aaron B. Mendelsohn, Young Hee Nam, James Marshall, Cara L. McDermott, Bharati Kochar, Michael D. Kappelman, Jeffrey S. Brown, and Catherine M. Lockhart
- Subjects
anti‐inflammatory ,biologics ,biosimilars ,dermatology ,gastroenterology ,patterns ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Abstract We report utilization patterns and characteristics of patients treated with biologic anti‐inflammatory agents in a large commercially insured patient population in the United States. We identified adult (age ≥18 years) patients receiving biologic anti‐inflammatory agents between 1 January 2012 and 31 March 2019 across the five Research Partners in the Biologic and Biosimilars Collective Intelligence Consortium's Distributed Research Network. We examined the number of incident use episodes for each biologic, as well as patient demographic and clinical characteristics. Curated data and analytic tools from the Food and Drug Administration's Sentinel System were used to perform the analyses. We identified 90,360 incident episodes of tumor necrosis factor‐alpha inhibitors (TNFi) and 70,506 incident episodes of non‐TNFi medications. Adalimumab was the most common TNFi drug (47% of all TNFi episodes) and showed a steady increase in utilization during the study period compared to other TNFi agents. Rituximab was the most commonly initiated non‐TNFi medication (44% of non‐TNFi episodes). Other non‐TNFi agents, namely, ustekinumab, vedolizumab, and secukinumab, demonstrated notable increases in utilization over time. Biosimilar use was limited; we observed 653 incident episodes for infliximab‐dyyb and 39 incident episodes for infliximab‐abda. As more biologics enter the market, greater variation in the use of biologics with similar indications and between biologic originators and biosimilars is anticipated. Because information on efficacy and safety at the time of drug approval is limited, post‐marketing surveillance and research is needed to monitor medication safety and evaluate effectiveness between biologic drugs using real‐world data.
- Published
- 2021
- Full Text
- View/download PDF
6. The quality of Medicaid and Medicare data obtained from CMS and its contractors: implications for pharmacoepidemiology
- Author
-
Charles E. Leonard, Colleen M. Brensinger, Young Hee Nam, Warren B. Bilker, Geralyn M. Barosso, Margaret J. Mangaali, and Sean Hennessy
- Subjects
Centers for Medicare and Medicaid Services (U.S.) ,Data accuracy ,Databases as a topic ,International Classification of Diseases ,Medicaid ,Medicare ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background Administrative claims of United States Centers for Medicare and Medicaid Services (CMS) beneficiaries have long been used in non-experimental research. While CMS performs in-house checks of these claims, little is known of their quality for conducting pharmacoepidemiologic research. We performed exploratory analyses of the quality of Medicaid and Medicare data obtained from CMS and its contractors. Methods Our study population consisted of Medicaid beneficiaries (with and without dual coverage by Medicare) from California, Florida, New York, Ohio, and Pennsylvania. We obtained and compiled 1999–2011 data from these state Medicaid programs (constituting about 38% of nationwide Medicaid enrollment), together with corresponding national Medicare data for dually-enrolled beneficiaries. This descriptive study examined longitudinal patterns in: dispensed prescriptions by state, by quarter; and inpatient hospitalizations by federal benefit, state, and age group. We further examined discrepancies between demographic characteristics and disease states, in particular frequencies of pregnancy complications among men and women beyond childbearing age, and prostate cancers among women. Results Dispensed prescriptions generally increased steadily and consistently over time, suggesting that these claims may be complete. A commercially-available National Drug Code lookup database was able to identify the dispensed drug for 95.2–99.4% of these claims. Because of co-coverage by Medicare, Medicaid data appeared to miss a substantial number of hospitalizations among beneficiaries ≥ 45 years of age. Pregnancy complication diagnoses were rare in males and in females ≥ 60 years of age, and prostate cancer diagnoses were rare in females. Conclusions CMS claims from five large states obtained directly from CMS and its contractors appeared to be of high quality. Researchers using Medicaid data to study hospital outcomes should obtain supplemental Medicare data on dual enrollees, even for non-elders. Trial Registration Not applicable.
- Published
- 2017
- Full Text
- View/download PDF
7. A Case of Sorafenib-induced DRESS Syndrome in Hepatocelluar Carcinoma
- Author
-
Dong Kyun Kim, Sung Woo Lee, Hwa Seong Nam, Dong Sub Jeon, Na Rae Park, Young Hee Nam, Soo Keol Lee, Yang Hyun Baek, Sang Young Han, and Sung Wook Lee
- Subjects
DRESS syndrome ,Sorafenib ,Hepatocellular carcinoma ,Medicine - Abstract
Sorafenib is currently the only targeted therapy available for advanced stage hepatocellular carcinoma (HCC). Cutaneous adverse events associated with sorafenib treatment include hand-foot skin reaction, but there has been no report of drug reaction (or rash) with eosinophilia and systemic symptoms (DRESS) syndrome. Here, we report a case of 72-year-old man with HCC and alcoholic liver cirrhosis who developed skin eruptions, fever, eosinophilia, and deteriorated hepatic and renal function under sorafenib treatment. He has since successfully recovered with conservative care. (Korean J Gastroenterol 2016;67:337-340)
- Published
- 2016
- Full Text
- View/download PDF
8. Correction: Nonsteroidal anti-inflammatory drug choice and adverse outcomes in clopidogrel users: A retrospective cohort study.
- Author
-
Young Hee Nam, Colleen M Brensinger, Warren B Bilker, Charles E Leonard, Scott E Kasner, Tilo Grosser, Xuanwen Li, and Sean Hennessy
- Subjects
Medicine ,Science - Abstract
[This corrects the article DOI: 10.1371/journal.pone.0193800.].
- Published
- 2018
- Full Text
- View/download PDF
9. Nonsteroidal anti-inflammatory drug choice and adverse outcomes in clopidogrel users: A retrospective cohort study.
- Author
-
Young Hee Nam, Colleen M Brensinger, Warren B Bilker, Charles E Leonard, Scott E Kasner, Tilo Grosser, Xuanwen Li, and Sean Hennessy
- Subjects
Medicine ,Science - Abstract
OBJECTIVE:To examine the comparative safety of individual NSAIDs when given concomitantly with clopidogrel. METHODS:We conducted a retrospective cohort study using Medicaid claims from five US states during 1999-2010, supplemented with Medicare claims for dual-enrollees. The exposure of interest was the first concomitant use of clopidogrel and one of the 10 selected NSAIDs after a 1-year baseline period. The outcomes were: all-cause mortality; acute myocardial infarction (AMI)/ischemic stroke; and gastrointestinal bleeding (GIB)/intracranial hemorrhage (ICH). We calculated the hazard ratio of each NSAID for each outcome, with ibuprofen as the reference drug, using high-dimensional propensity score-adjusted proportional-hazards regression models. RESULTS:Of 1,060,412 clopidogrel users, 268,114 concomitant NSAID users met inclusion/exclusion criteria, contributing 48,483 person-years. We observed 2,463 deaths, 2,822 AMI/ischemic stroke outcomes, and 2,620 GIB/ICH outcomes, for unadjusted incidence rates of 50.8, 58.6, and 54.3 per 1,000 person-years, respectively. Compared with ibuprofen and controlling for potential confounders, rofecoxib (hazard ratio [HR] = 1.22; 95% confidence interval [CI]: 1.04, 1.43) and valdecoxib (HR = 0.66; 95% CI: 0.48, 0.92) showed higher and lower hazards of mortality, respectively. Indomethacin showed an increased AMI/ischemic stroke hazard (HR = 1.38; 95% CI: 1.09, 1.74). For GIB/ICH, indomethacin (HR = 2.18; 95% CI: 1.74, 2.73), diclofenac (HR = 1.65; 95% CI: 1.39, 1.97), naproxen (HR = 1.47; 95% CI: 1.28, 1.70), and rofecoxib (HR = 1.26; 95% CI: 1.08, 1.48) showed higher hazards, and valdecoxib (HR = 0.73; 95% CI: 0.55, 0.98) showed a lower hazard. CONCLUSION:The bleeding risks of individual NSAIDs varied more markedly than thrombotic risks when used concomitantly with clopidogrel. Moreover, bleeding risk and thrombotic risk among individual NSAIDs did not appear to be inversely related to each other in the presence of clopidogrel. Further studies are needed to elucidate underlying biological mechanisms and help clinical decision-making for a better NSAID choice in clopidogrel users.
- Published
- 2018
- Full Text
- View/download PDF
10. Effect of biologic therapies on quality of life in severe asthma: Findings from the PRISM study
- Author
-
Hyo-In Rhyou, MD, PhD, Hyun-Kyoung Kim, MPH, Woo-Jung Song, MD, PhD, Sang Min Lee, MD, PhD, Sang-Ha Kim, MD, PhD, Jae-Woo Kwon, MD, PhD, Han-Ki Park, MD, PhD, Hye-Kyung Park, MD, PhD, Sang Hoon Kim, MD, PhD, Jeong-Hee Choi, MD, PhD, Sujeong Kim, MD, PhD, So-Young Park, MD, PhD, Sae-Hoon Kim, MD, PhD, Ji-Yong Moon, MD, PhD, Jae-Woo Jung, MD, PhD, Young-Joo Cho, MD, PhD, Chan Sun Park, MD, PhD, Byung Keun Kim, MD, PhD, Joo-Hee Kim, MD, PhD, Min-Suk Yang, MD, PhD, Min-Hye Kim, MD, PhD, Young-Hee Nam, MD, PhD, Taehoon Lee, MD, PhD, Byung-Jae Lee, MD, PhD, Pankaj Bhavsar, PhD, Ian M. Adcock, PhD, Kian Fan Chung, MD, DSc, and Tae-Bum Kim, MD, PhD
- Subjects
Severe asthma ,Quality of life ,Biologics ,Anti-IL-5 ,Anti-IL-4/IL-13 ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Background: Anti-type 2 (T2) biologic therapies (biologics) improve exacerbation rates, lung function, and asthma-related quality of life (QoL) in patients with severe T2 asthma. However, studies comparing different biologics are lacking. We evaluated the QoL in patients with severe asthma comprehensively and compare the efficacy of different T2-directed biologics using QoL questionnaires. Methods: We compared the QoL between severe and mild-to-moderate asthma and between severe asthma with and without biologics treatment. Data of mild-to-moderate were extracted from the Cohort for Reality and Evolution of Adult Asthma in Korea, and data of severe asthma were collected from the Precision Medicine Intervention in Severe Asthma. We included 183 patients with severe asthma treated with T2 biologics or conventional therapy between April 2020 and May 2021 and assessed QoL of them using the Questionnaire for Adult Korean Asthmatics (QLQAKA), Severe Asthma Questionnaire (SAQ), and EuroQoL-5Dimensions (EQ-5D) at baseline and 6 months. Results: The EQ-5D index (0.803) of severe asthma was lower than that of other chronic diseases representing a worse QoL. The scores for all questions of QLQAKA, except “cough,” were lower (less control) in the severe asthma group than in the mild-to-moderate asthma group at baseline and 6 months (P 0.05). Conclusion: QoL was worse in severe asthma than in mild-to-moderate asthma and other chronic diseases. T2 biologics equally improved QoL in patients with severe asthma.
- Published
- 2024
- Full Text
- View/download PDF
11. The US Food and Drug Administration Sentinel System: a national resource for a learning health system.
- Author
-
Jeffrey S. Brown, Aaron B. Mendelsohn, Young Hee-Nam, Judith C. Maro, Noelle M. Cocoros, Carla Rodriguez-Watson, Catherine M. Lockhart, Richard Platt, Robert Ball, Gerald J. Dal Pan, and Sengwee Toh
- Published
- 2022
- Full Text
- View/download PDF
12. Rewritten Life and Music Activities of Composer Lee Sang-Keun
- Author
-
Young-Hee Nam
- Subjects
General Medicine - Published
- 2023
13. Wartime Capital Busan during the Korean War and the Film 〈Nakdonggang River〉
- Author
-
Young-hee Nam and Soon-wook Lee
- Subjects
Ocean Engineering ,Safety, Risk, Reliability and Quality - Published
- 2022
14. Troop Information and Education Music in Busan during the Korean War
- Author
-
Young-Hee Nam
- Published
- 2022
15. Nonepisodic angioedema with eosinophilia after COVID-19 vaccination: a case successfully treated with reslizumab
- Author
-
Young-Hee Nam
- Subjects
General Medicine - Abstract
Background Angioedema with eosinophilia (AE) is a rare allergic disease classified as episodic or nonepisodic. AE is characterized by angioedema, urticaria, fever, weight gain, and eosinophilia, but its etiology and pathogenesis have not yet been clarified. Case presentations We present a 70-year-old woman presented with generalized edema and urticaria after Moderna COVID-19 vaccination. Peripheral blood eosinophil count was marked elevated and echocardiography and Doppler ultrasonography of both the upper and lower extremities were unremarkable. Her symptoms and peripheral blood eosinophil count were improved after systemic steroid therapy, but she failed to respond to steroid tapering. Reslizumab (anti-interluekin-5) was administered intravenously, and she remained symptom free with a normal eosinophil count during 8 months of reslizumab treatment without steroids. Conclusions We report a case of nonepisodic AE after COVID-19 vaccination that was successfully treated with reslizumab.
- Published
- 2023
16. Multicenter Prospective Observational Study to Evaluate the Therapeutic Effect and Safety of a Combination of Montelukast and Levocetirizine for Allergic Rhinitis when Administered to Patients with Allergic Rhinitis and Asthma
- Author
-
Min-Hye Kim, Kyoung-Hee Sohn, Hye Jung Park, Young Hee Nam, Mi-Hye Kim, Jae-Woo Jung, Jae-Woo Kwon, Yoo Seob Shin, Jong-Sook Park, Young-Joo Cho, Choon-Sik Park, and Byoung Whui Choi
- Subjects
Cyclopropanes ,Drug Combinations ,Treatment Outcome ,Immunology ,Quality of Life ,Quinolines ,Humans ,Immunology and Allergy ,General Medicine ,Acetates ,Rhinitis, Allergic ,Asthma - Abstract
Introduction: Allergic rhinitis and asthma share a common inflammatory mechanism and are closely related, recognized as “one airway disease.” Thus, the guidelines recommend allergic rhinitis and asthma be treated together, and leukotriene antagonists and antihistamines have been administered simultaneously; however, there are few reports of the use of combination drugs so far. Methods: The aim of the study was to evaluate the treatment effects and adverse events of Monterizine® (a combination of montelukast and levocetirizine); a total of 2,254 patients with perennial allergic rhinitis and asthma were prospectively enrolled from 60 hospitals nationwide in Korea. They were followed up for 3 (Period 1) or 6 months (Period 2). Total nasal symptom score (TNSS), satisfaction, and safety data were collected and compared to baseline. Results: TNSS scores were analyzed for 2,254 subjects. At Period 1 (n = 2,024) and 2 (n = 1,861), the scores decreased significantly from baseline (−1.20 ± 2.49 and −1.63 ± 2.78, p < 0.001). The mean quality of life (QoL) was significantly improved at Period 1 and 2 relative to baseline (−3.75 ± 6.58, −4.83 ± 7.11, both p < 0.0001). There were no serious adverse drug reactions, but there were some minor reactions including nasopharyngitis (2.92%), rhinitis (0.37%), and somnolence (0.34%). Conclusions: TNSS score and QoL were significantly improved by 3–6 months’ treatment with Monterizine without significant adverse reactions. These results indicate that Monterizine, as a combination drug, is effective and safe for improving nasal symptoms and quality of life in patients with allergic rhinitis who also have asthma.
- Published
- 2022
17. A Study on Music Education Institution and Music Education in Busan during the Liberation Period
- Author
-
Young-hee Nam and Soon-wook Lee
- Published
- 2021
18. 1462. Validating a claims-based algorithm for Lyme Disease in Massachusetts
- Author
-
Sheryl A Kluberg, Sarah J Willis, Noelle M Cocoros, Susan R Forrow, Emma R Hoffman, Robert M Jin, Aaron M Mendelsohn, Young Hee Nam, Bradford J Gessner, Sarah J Pugh, James H Stark, Cameron T Nutt, Nathan Petrou, Chanu Rhee, Meera Sury, and John Aucott
- Subjects
Infectious Diseases ,Oncology - Abstract
Background Lyme disease (LD) is the fifth most reported notifiable disease in the US, but the true disease burden remains unknown due to inconsistent reporting. Claims-based algorithms estimate a ≥10-fold higher incidence compared to notifiable-disease surveillance, but these algorithms are unvalidated. Methods We evaluated a claims-based LD algorithm based on ICD codes (ICD-9-CM 088.81 or ICD-10-CM A69.2X) and a ≥7-day course of an antibiotic used to treat LD dispensed ±30 days of diagnosis. We applied the LD algorithm to Harvard Pilgrim Health Care (HPHC) claims data for Massachusetts (MA) residents. We sought health records for patients who met the algorithm between Jan 2015 and June 2019 and received care within the Massachusetts General Brigham (MGB) system at diagnosis. Three clinicians received training on case classification and conducted chart abstractions and adjudications. Cases were classified as confirmed, probable, suspect, or ruled out using 2017 CDC case definitions. To assess inter-rater reliability, the clinicians abstracted and adjudicated the same 20 charts; we computed the mean of kappa for each clinician-pair. We calculated the positive predictive value (PPV) of the algorithm for identifying confirmed, probable, or suspect LD cases, all of which required at least erythema migrans (EM) or clinical diagnosis with confirmatory serology and antibiotics prescription. Results We identified 11,823 HPHC members who met the LD algorithm. Of these members, 171 cases occurred within the study period among MGB patients; we obtained 128 (75%) patients’ charts for review. The average weighted kappa statistic of adjudicator agreement was 0.94. Of the reviewed charts, 103 (80.5%) were adults ≥ 18 years old. 71 patients (55.5%) were clinically diagnosed with LD, among whom 62 (48.4%) presented with EM rash. 24 reviewed cases (18.8%) had laboratory-confirmed LD. LD was ruled out for 8 cases. The overall algorithm PPV was 93.8% (95% CI 89.6-97.9%). Limited to confirmed and probable cases only, the PPV was 66.4% (95% CI 57.5-74.5%). Conclusion A claims-based algorithm combining diagnosis codes and antibiotic prescriptions identified LD cases in MA with high PPV. This algorithm could be used to describe the incidence of LD in regions with similar diagnostic, treatment, and coding practices. Disclosures Sheryl A. Kluberg, PhD, SM, GlaxoSmithKline: Grant/Research Support|Pfizer, Inc.: Support for the project described in the abstract Sarah J. Willis, PhD, MPH, Pfizer: Employment|Pfizer: Conducted Pfizer funded research while employed by Harvard Pilgrim Health Care Institute Noelle M. Cocoros, DSc, MPH, Pfizer: PI on study Bradford J. Gessner, M.D., M.P.H., Pfizer Inc.: Employee|Pfizer Inc.: Stocks/Bonds Sarah J. Pugh, PhD, MPH, Pfizer, Inc: Employee|Pfizer, Inc: Stocks/Bonds James H. Stark, PhD, Pfizer: Employee|Pfizer: Stocks/Bonds Chanu Rhee, MD, MPH, Cytovale: Advisor/Consultant|Pfizer: Advisor/Consultant|UpToDate, Inc.: Royalties.
- Published
- 2022
19. Investigating barriers to electronic medical record use during collaborative information seeking activities.
- Author
-
Arvind Karunakaran, Young Hee-Nam, and Madhu C. Reddy
- Published
- 2012
- Full Text
- View/download PDF
20. Analysis of factors related to suicidal ideation among people with and without disabilities in elderly living alone
- Author
-
Young-Hee Nam and YeSoon Kim
- Subjects
medicine.medical_specialty ,business.industry ,Medicine ,medicine.symptom ,business ,Psychiatry ,Suicidal ideation - Published
- 2021
21. The Psychological Relieving Effect of Drug Provocation Test in Drug Hypersensitivity
- Author
-
Hyo-In Rhyou and Young-Hee Nam
- Subjects
Pulmonary and Respiratory Medicine ,Journal of Asthma and Allergy ,Immunology and Allergy - Abstract
Hyo-In Rhyou,1 Young-Hee Nam2 1Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea; 2Department of Internal Medicine, College of Medicine, Dong-A University Hospital, Busan, KoreaCorrespondence: Young-Hee Nam, Department of Internal Medicine, College of Medicine, Dong-A University, 26 Daesingongwon-ro, Seo-Gu, Busan, Korea, Tel +8251-240-5860, Fax +82-51-242-5864, Email yhnam@dau.ac.krPurpose: Drug hypersensitivity is an adverse drug reaction mediated by immunological mechanisms and is accompanied by a significant socioeconomic burden. The drug provocation test (DPT) is the gold standard for drug allergy diagnosis; however, a standardized protocol does not exist. This study aimed to investigate the effects of psychological relief from DPT in patients with drug hypersensitivity.Patients and Methods: A total of 46 patients who had experienced drug hypersensitivity were administered DPT after admission to our clinic at Dong-A University Hospital and asked to complete the questionnaires before and after DPT. Anxiety and depressive symptom levels were assessed using the Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI)-II, respectively.Results: There was a significant decrease in the BAI and BDI-II scores after DPT than before DPT, respectively (BAI: 10.22 ± 10.75 vs 7.26 ± 6.95, P=0.025; BDI-II: 13.00 ± 7.92 vs 11.17 ± 7.80, P = 0.019). Twenty-two patients with non-anaphylactic drug hypersensitivity showed a significant decrease in the BDI-II scores after DPT (11.50 ± 7.60 vs 9.50 ± 5.98, P = 0.009), but not in the BAI scores (8.45 ± 7.41 vs 6.18 ± 4.58, P = 0.127). However, there were no statistically significant differences in the BDI-II and BAI scores before and after DPT (BAI: 11.83 ± 13.05 vs 8.25 ± 8.56, P = 0.664; BDI-II: 14.38 ± 8.11 vs 12.71 ± 9.01, P = 0.215) in 24 patients with anaphylaxis.Conclusion: DPT may reduce the psychological burden in patients with drug hypersensitivity, especially in those without anaphylaxis.Keywords: drug hypersensitivity, diagnostic test, anxiety, depression
- Published
- 2022
22. The US Food and Drug Administration Sentinel System: a national resource for a learning health system
- Author
-
Jeffrey S Brown, Aaron B Mendelsohn, Young Hee Nam, Judith C Maro, Noelle M Cocoros, Carla Rodriguez-Watson, Catherine M Lockhart, Richard Platt, Robert Ball, Gerald J Dal Pan, and Sengwee Toh
- Subjects
Pharmaceutical Preparations ,United States Food and Drug Administration ,Health Informatics ,Learning Health System ,United States ,Perspectives - Abstract
The US Food and Drug Administration (FDA) created the Sentinel System in response to a requirement in the FDA Amendments Act of 2007 that the agency establish a system for monitoring risks associated with drug and biologic products using data from disparate sources. The Sentinel System has completed hundreds of analyses, including many that have directly informed regulatory decisions. The Sentinel System also was designed to support a national infrastructure for a learning health system. Sentinel governance and guiding principles were designed to facilitate Sentinel’s role as a national resource. The Sentinel System infrastructure now supports multiple non-FDA projects for stakeholders ranging from regulated industry to other federal agencies, international regulators, and academics. The Sentinel System is a working example of a learning health system that is expanding with the potential to create a global learning health system that can support medical product safety assessments and other research.
- Published
- 2022
23. HLA‐A*24:02 increase the risk of allopurinol‐induced drug reaction with eosinophilia and systemic symptoms in HLA‐B*58:01 carriers in a Korean population; a multicenter cross‐sectional case‐control study
- Author
-
Mi‐Yeong Kim, James Yun, Dong‐Yoon Kang, Tae Hee Kim, Min‐Kyung Oh, Sunggun Lee, Min‐Gyu Kang, Young‐Hee Nam, Jeong‐Hee Choi, Min‐Suk Yang, Seung Seok Han, Hajeong Lee, Hyun‐Jai Cho, Jaeseok Yang, Kook‐Hwan Oh, Yon Su Kim, Jae Woo Jung, Kye Hwa Lee, and Hye‐Ryun Kang
- Subjects
Pulmonary and Respiratory Medicine ,Immunology ,Immunology and Allergy - Abstract
HLA-B*58:01 is a well-known risk factor for allopurinol-induced severe cutaneous adverse reactions (SCARs). However, only a minority of HLA-B*58:01 carriers suffer SCARs after taking allopurinol. The aim of this study was to investigate subsidiary genetic markers that could identify those at further increased risk of developing allopurinol-induced drug reaction with eosinophilia and systemic symptoms (DRESS) in subjects with HLA-B*58:01.Subjects with B*58:01 were enrolled (21 allopurinol-induced DRESS and 52 allopurinol-tolerant control). HLA-A, -B, -C and -DRB1 alleles were compared. Comparison of risk between HLAs and allopurinol-induced SCAR in separate populations was performed to support the results. Kruskal-Wallis test, Pearson's chi-square test, Fisher's exact test and binary logistic regression were used to analyze the risk of SCAR development.Frequencies of A*24:02 (71.4 vs. 17.3%,The additional secondary screening with A*24:02 and DRB1*13:02 alleles may identify those at further increased risk of allopurinol-induced DRESS in B*58:01 carriers.
- Published
- 2022
24. Clinical predictors of treatment response to tiotropium add-on therapy in adult asthmatic patients: From multicenter real-world cohort data in Korea
- Author
-
Ji-Su Shim, Juhae Jin, Sae-Hoon Kim, Taehoon Lee, An-Soo Jang, Chan Sun Park, Jae-Woo Jung, Jae-Woo Kwon, Ji-Yong Moon, Min-Suk Yang, Jaechun Lee, Jeong-Hee Choi, Yoo Seob Shin, Hee-Kyoo Kim, Sujeong Kim, Joo-Hee Kim, Sang-Heon Cho, Young-Hee Nam, Sang-Hoon Kim, So Young Park, Gyu Young Hur, Sang-Ha Kim, Hye-Kyung Park, Hyun Jung Jin, Jae-Hyun Lee, Jung-Won Park, Ho Joo Yoon, Byoung Whui Choi, Young-Joo Cho, Min-Hye Kim, and Tae-Bum Kim
- Subjects
Pulmonary and Respiratory Medicine ,Immunology ,Immunology and Allergy - Abstract
Tiotropium, a long-acting muscarinic antagonist, is recommended for add-on therapy to inhaled corticosteroids (ICS)-long-acting beta 2 agonists (LABA) for severe asthma. However, real-world studies on the predictors of response to tiotropium are limited. We investigated the real-world use of tiotropium in asthmatic adult patients in Korea and we identified predictors of positive response to tiotropium add-on.We performed a multicenter, retrospective, cohort study using data from the Cohort for Reality and Evolution of Adult Asthma in Korea (COREA). We enrolled asthmatic participants who took ICS-LABA with at least 2 consecutive lung function tests at 3-month intervals. We compared tiotropium users and non-users, as well as tiotropium responders and non-responders to predict positive responses to tiotropium, defined as 1) increase in forced expiratory volume in 1 s (FEV1) ≥ 10% or 100 mL; and 2) increase in asthma control test (ACT) score ≥3 after 3 months of treatment.The study included 413 tiotropium users and 1756 tiotropium non-users. Tiotropium users had low baseline lung function and high exacerbation rate, suggesting more severe asthma. Clinical predictors for positive response to tiotropium add-on were 1) positive bronchodilator response (BDR) [odds ratio (OR) = 6.8, 95% confidence interval (CI): 1.6-47.4, P = 0.021] for FEV1 responders; 2) doctor-diagnosed asthma-chronic obstructive pulmonary disease overlap (ACO) [OR = 12.6, 95% CI: 1.8-161.5,The results of this study suggest that tiotropium add-on for uncontrolled asthma with ICS-LABA would be more effective in patients with positive BDR or ACO. Additionally, an increase in FEV1 following tiotropium may predict a lower risk of asthma exacerbation.
- Published
- 2022
25. Using the IMEDS distributed database for epidemiological studies in type 2 diabetes mellitus
- Author
-
Ting-Ying Huang, Carla Rodriguez-Watson, Tongtong Wang, Shawna R Calhoun, James Marshall, Jillian Burk, Young Hee Nam, Aaron B Mendelsohn, Aziza Jamal-Allial, Robert T Greenlee, Mano Selvan, Pamala A Pawloski, Cheryl N McMahill Walraven, Ashish Rai, Sengwee Toh, and Jeffery S Brown
- Subjects
Adult ,Male ,Diabetes Mellitus, Type 2 ,Endocrinology, Diabetes and Metabolism ,Humans ,Hypoglycemic Agents ,Insulin ,Female ,Metformin ,Aged ,Retrospective Studies - Abstract
IntroductionThis study aimed to assess data relevancy and data quality of the Innovation in Medical Evidence Development and Surveillance System Distributed Database (IMEDS-DD) for diabetes research and to evaluate comparability of its type 2 diabetes cohort to the general type 2 diabetes population.Research design and methodsA retrospective study was conducted using the IMEDS-DD. Eligible members were adults with a medical encounter between April 1, 2018 and March 31, 2019 (index period). Type 2 diabetes and co-existing conditions were determined using all data available from April 1, 2016 to the most recent encounter within the index period. Type 2 diabetes patient characteristics, comorbidities and hemoglobin A1c(HbA1c) values were summarized and compared with those reported in national benchmarks and literature.ResultsType 2 diabetes prevalence was 12.6% in the IMEDS-DD. Of 4 14 672 patients with type 2 diabetes, 52.8% were male, and the mean age was 65.0 (SD 13.3) years. Common comorbidities included hypertension (84.5%), hyperlipidemia (82.8%), obesity (45.3%), and cardiovascular disease (44.7%). Moderate-to-severe chronic kidney disease was observed in 20.2% patients. The most commonly used antihyperglycemic agents included metformin (35.7%), sulfonylureas (14.8%), and insulin (9.9%). Less than one-half (48.9%) had an HbA1cvalue recorded. These findings demonstrated the notable similarity in patient characteristics between type 2 diabetes populations identified within the IMEDS-DD and other large databases.ConclusionsDespite the limitations related to HbA1cdata, our findings indicate that the IMEDS-DD contains robust information on key data elements to conduct pharmacoepidemiological studies in diabetes, including member demographic and clinical characteristics and health services utilization.
- Published
- 2022
26. Comparison of ADL and QoL for the Osteoporosis and Non-osteoporosis in elderly people with disabilities
- Author
-
YeSoon Kim and Young-Hee Nam
- Subjects
Gerontology ,business.industry ,Osteoporosis ,medicine ,Elderly people ,medicine.disease ,business - Published
- 2021
27. Clinical characteristics and risk factors for cefaclor-induced immediate hypersensitivity: a retrospective observation at two university hospitals in Korea
- Author
-
Go-Eun Doo, Young Min Ye, Chae-Yeon Ha, Young-Hee Nam, Youngsoo Lee, Hee-Joo Nam, Sung-Dae Woo, Ji-Won Yoon, and Hyo-In Rhyou
- Subjects
lcsh:Immunologic diseases. Allergy ,medicine.medical_specialty ,Allergy ,Immediate ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Pharmacovigilance ,medicine ,polycyclic compounds ,Hypersensitivity ,030212 general & internal medicine ,Risk factor ,Cefaclor ,Asthma ,Clinical characteristics ,business.industry ,Incidence (epidemiology) ,Research ,Incidence ,Retrospective cohort study ,General Medicine ,Odds ratio ,medicine.disease ,030228 respiratory system ,business ,lcsh:RC581-607 ,medicine.drug - Abstract
Background Cefaclor, a second-generation oral cephalosporin, is widely prescribed to treat infectious diseases. Immediate hypersensitivity (HS) reactions to cefaclor have continuously been reported and are expected to increase with its greater use. This study aimed to investigate the clinical characteristics and risk factors of immediate HS to cefaclor over the most recent 5 years. Methods This retrospective study investigated 521 adverse drug reactions (ADRs) to cefaclor at pharmacovigilance centers at two tertiary hospitals from January 2014 to December 2018. In total, 459 patients with immediate HS to cefaclor were reviewed. Results A total of 459 cases of cefaclor immediate HS were included among 521 cefaclor ADRs, and anaphylaxis was recorded in 61.2%. Female sex (odds ratio 2.917, 95% confidence interval 2.397–3.550, P P P P = 0.010), asthma (8.075, 5.301–12.302, P P Conclusions Cefaclor was found to elicit high proportions of immediate HS and anaphylaxis. Physicians ought to be cautious with prescribing cefaclor to females, individuals with hypertension, liver diseases, or asthma, and patients taking nonsteroidal anti-inflammatory drugs. Trial registration This study was retrospectively registered.
- Published
- 2021
28. Affecting Factors for Activity of Daily Living and Suicidal Ideation in Elderly Person with Disabilities: Based on the 2017 Korea National Survey of the Disabled
- Author
-
YeSoon Kim and Young-Hee Nam
- Subjects
Gerontology ,Activities of daily living ,medicine ,medicine.symptom ,Psychology ,Suicidal ideation - Published
- 2020
29. Anxiety, depression, and stress in Korean patients with chronic urticaria
- Author
-
Eun-Jung Jo, Hye-Kyung Park, Hee-Kyoo Kim, Chan Sun Park, Young-Hee Nam, Mi-Yeong Kim, and Gil-Soon Choi
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Allergy ,Anxiety depression ,Affect (psychology) ,Hospital Anxiety and Depression Scale ,chronic urticaria ,Young Adult ,stress ,Quality of life ,Surveys and Questionnaires ,Internal medicine ,Republic of Korea ,Humans ,Medicine ,Chronic urticaria ,Depression (differential diagnoses) ,Aged ,Asthma ,business.industry ,Middle Aged ,anxiety ,medicine.disease ,psychiatric disorders ,Chronic Disease ,depression ,Quality of Life ,Anxiety ,Female ,Original Article ,medicine.symptom ,business - Abstract
Background/Aims Emotional distress is thought to cause or maintain chronic urticaria (CU). We aimed to investigate the presence of anxiety, depression, and stress in Korean adult CU patients and to explore their potential impact on treatment. Methods We enrolled 79 CU patients and a disease control group comprising 39 persistent asthma patients. The Hospital Anxiety and Depression Scale (HADS) was used to evaluate depression and anxiety. Stress and quality of life (QoL) were assessed by Stress Response Inventory and CU-QoL questionnaires. The sociodemographic and clinical data such as urticaria activity score (UAS-15, UAS-6) were obtained. Results The prevalence of depression and anxiety based on the HADS were 48.1% and 38.0%. Although the prevalence of anxiety didn’t differ between the CU and asthma patients, depression was significantly more prevalent in the CU patients (48.1% vs. 28.2%). Stress tended to be lower in CU patients. Anxiety, depression, and stress exhibited negative correlations with QoL. Anxiety showed significant correlation with UAS-6 and pruritus-visual analog scale (VAS; r = 0.256, r = 0.272, p < 0.05, respectively); depression correlated with sleep difficulty-VAS (r = 0.261, p < 0.05). Stress was associated with UAS-15, UAS-6, pruritus-VAS, and sleep difficulty-VAS (r = 0.251, r = 0.317, r = 0.302, r = 0.258, p < 0.05, respectively). Conclusions The current study first presented that Korean CU patients frequently have anxiety and depression, which affect their QoL and demonstrated that anxiety, depression, and stress had different effects on sleep difficulty, pruritus, and urticaria severity in Korean CU patients.
- Published
- 2020
30. The burden of symptomatic patients with chronic spontaneous urticaria: a real-world study in Korea
- Author
-
Young-Min Ye, Young-Il Koh, Jeong-Hee Choi, Mi-Ae Kim, Jung-Won Park, Tae-Bum Kim, Young-Hee Nam, Yoon-Seok Chang, and Hae-Sim Park
- Subjects
Cross-Sectional Studies ,Urticaria ,Chronic Disease ,Republic of Korea ,Quality of Life ,Humans ,Chronic Urticaria ,Copper ,Retrospective Studies - Abstract
Background/Aims: Chronic spontaneous urticaria (CSU) poses a considerable burden both on the quality of life (QoL) of individual patients and on healthcare systems. Real‑world data evaluating the disease burden of CSU are limited in this country. This study evaluated the disease burden and healthcare resource utilization (HRU) among symptomatic CSU patients.Methods: This multicenter, noninterventional, retrospective, and cross-sectional study assessed CSU patients symptomatic for more than 6 months despite step-wise H1-antihistamine medications. Primary outcomes included Urticaria Activity Score over 7 days (UAS7) and Chronic Urticaria QoL scale (CU-QoL). Secondary outcomes included EuroQol 5-Dimension 5-Level (EQ-5D-5L), Dermatology Life Quality Index (DLQI), association of disease activity with QoL, medications used for the past 6 months, and HRU.Results: Five hundred patients with CSU were enrolled. Mean disease duration was 3.7 years. Based on UAS7, 22.2% of patients were in well-controlled status and 31.2%, 28.4%, and 18.2% of them had mild, moderate, and severe disease, respectively. Mean CU-QoL and DLQI scores were 57.5 ± 29.7 and 10.2 ± 7.6, respectively, while the EQ-5D-5L utility score was 0.8 ± 0.2. H1-antihistamines were prescribed to 95% of patients, while omalizumab was prescribed to 33% of patients. Most patients (98%) had outpatient visits in the past 6 months. Negative correlations were noted between UAS7 and CU-QoL, EQ-5D-5L, EQ-5D-5L visual analog scale scores, but a positive correlation was noted with DLQI score (p < 0.001 for all). The number of outpatient department visits increased with disease activity (p = 0.001).Conclusions: CSU affects QoL, leading to increased HRU, particularly in patients with severe disease.
- Published
- 2022
31. Analysis of the Effect of Improving Posture Balance and Muscular Strength after Applying the Health Gymnastics Program for the Elderly
- Author
-
Byung-kook Son and Young-hee Nam
- Subjects
medicine.medical_specialty ,Physical medicine and rehabilitation ,medicine ,Postural Balance ,Physical strength ,Psychology ,Balance (ability) - Published
- 2020
32. Present Status and Challenges of Youth Culture and Art in Jeju
- Author
-
Jin-Chul Kim, Young-Hee Nam, Min-Kyoung Jeong, and Soon-Wook Lee
- Subjects
Gender studies ,Sociology ,Youth culture - Published
- 2020
33. Predictive factors of response to inhaled corticosteroids in newly diagnosed asthma
- Author
-
Hyo-In Rhyou and Young-Hee Nam
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Exacerbation ,Inhalation ,business.industry ,Immunology ,Inhaled corticosteroids ,Eosinophil ,medicine.disease ,respiratory tract diseases ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,030228 respiratory system ,Internal medicine ,Absolute neutrophil count ,medicine ,Immunology and Allergy ,Sputum ,Observational study ,030212 general & internal medicine ,medicine.symptom ,business ,Asthma - Abstract
Background Asthma is characterized by chronic airway inflammation, and inhaled corticosteroids (ICSs) have been recommended as first-line treatment. However, response to ICS treatment is various, and the prediction of response to ICSs is still difficult, especially in individuals with newly diagnosed asthma. Objective To assess the clinical factors and biomarkers associated with response to ICSs in newly diagnosed asthma. Methods A total of 150 ICS-naive patients with newly diagnosed asthma in the allergy clinic of a single tertiary hospital in Korea from January 2014 to January 2019 were included in this study. All patients initially received moderate-dose ICSs and were treated for more than 1 year. We compared the clinical characteristics and parameters between patients with and without acute exacerbation (AE) during the study period. Results In this study, 99 patients had no AE (stable asthma group), and 51 patients presented with more than 1 AE (unstable asthma group). The mean (SD) blood eosinophil count (635.7 [780.3] × 103/μL vs 373.4 [266.8] × 103/μL, P = .003) and sputum eosinophil count (15.2% [23.9%] vs 8.3% [15.4%], P = .051) were higher and the sputum neutrophil count (42.9% [35.1%] vs 61.3% [35.1%], P = .057) was lower in the stable asthma group than in the unstable asthma group. Conclusion High blood and sputum eosinophil counts can predict a good response to ICS treatment in terms of prevention of AE in individuals with newly diagnosed asthma. The sputum neutrophil count may be an effective predictor of response to ICSs, even though additional studies must be conducted.
- Published
- 2020
34. An Analysis of the Research Trends of Health Information Managers in Korea (1999-2018)
- Author
-
Young-Hee Nam and Hyun Jung
- Subjects
business.industry ,Health information ,Public relations ,business - Published
- 2020
35. Sulfonylureas and Metformin Were Not Associated With an Increased Rate of Serious Bleeding in Warfarin Users: A Self‐Controlled Case Series Study
- Author
-
Young Hee Nam, Warren B. Bilker, Sean Hennessy, Xu Han, Charles E. Leonard, and Colleen M. Brensinger
- Subjects
Adult ,Male ,medicine.medical_specialty ,Gastrointestinal bleeding ,Adolescent ,Hemorrhage ,Risk Assessment ,030226 pharmacology & pharmacy ,Article ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Humans ,Hypoglycemic Agents ,Medicine ,Drug Interactions ,Pharmacology (medical) ,Aged ,Aged, 80 and over ,Pharmacology ,Medicaid ,business.industry ,Warfarin ,Anticoagulants ,Middle Aged ,medicine.disease ,Metformin ,United States ,Confidence interval ,Glimepiride ,Sulfonylurea Compounds ,030220 oncology & carcinogenesis ,Concomitant ,Female ,business ,medicine.drug ,Case series ,Glipizide - Abstract
Drug interactions between warfarin and sulfonylureas are suggested by pharmacokinetic information and prior studies. However, clinical evidence on the association of such interactions and the risk of bleeding is lacking. Using healthcare claims data from 5 US Medicaid programs from 1999-2011 and a self-controlled case series design with warfarin as an object drug, we calculated confounder-adjusted rate ratios (RRs) for concomitant use of sulfonylureas and metformin for 3 outcomes separately: (i) serious bleeding as a composite outcome of gastrointestinal bleeding (GIB) and nontraumatic intracranial hemorrhage (ICH); (ii) GIB; and (iii) ICH. In 6,463 warfarin users experiencing serious bleeding, an increased rate of serious bleeding was not associated with concomitant use of glimepiride (RR: 0.93; 95% confidence interval (CI) 0.75-1.15), glipizide (RR: 0.97; 95% CI 0.84-1.13), glyburide (RR: 0.89; 95% CI 0.76-1.06), or metformin (RR: 0.85; 95% CI 0.76-0.96), nor was the occurrence of the component outcomes of GIB or ICH. These results suggest that use of sulfonylureas or metformin was not associated with an increased rate of serious bleeding in warfarin users.
- Published
- 2020
36. The Effects of Foreign Workers' Health Beliefs on Health Behavior
- Author
-
Young Hee Nam
- Subjects
Health belief model ,Health education ,Health behavior ,Psychology ,Social psychology - Published
- 2020
37. A Comparative Study on the Effect of e-Health Literacy, Health Information Reliability and Health Behavior on the Health Information Use Motive in Korean and Chinese University Students
- Author
-
In Suk Jung and Young Hee Nam
- Subjects
Medical education ,Health literacy ,Health information ,Health behavior ,Psychology ,Reliability (statistics) - Published
- 2020
38. The Effect of Physical Activity Program of Elderly in Rural Areas on Life Satisfaction
- Author
-
Young Hee Nam
- Subjects
Gerontology ,Aging ,General Health Professions ,Physical activity ,Life satisfaction ,Dentistry (miscellaneous) ,Rural area ,Psychology ,Health Professions (miscellaneous) ,Biochemistry, Genetics and Molecular Biology (miscellaneous) ,General Dentistry ,General Biochemistry, Genetics and Molecular Biology - Published
- 2020
39. Clinical aspects of severe cutaneous adverse reactions caused by beta-lactam antibiotics: A study from the Korea SCAR registry
- Author
-
Min-Hye Kim, Dong Yoon Kang, Young-Hee Nam, Da Woon Sim, Sujeong Kim, Jun Kyu Lee, Jung-Won Park, Hye-Kyung Park, Jae-Woo Jung, Cheol-Woo Kim, Min-Suk Yang, Joo-Hee Kim, Young-Min Ye, Young-Il Koh, Hye-Ryun Kang, Seoung Ju Park, and Sae-Hoon Kim
- Subjects
Pulmonary and Respiratory Medicine ,Immunology ,Immunology and Allergy - Published
- 2023
40. A study on the injury prediction of LOS, discharge results, ICU
- Author
-
Young-Hee Nam
- Subjects
medicine.medical_specialty ,business.industry ,Emergency medicine ,Medicine ,business ,Injury prediction - Published
- 2019
41. Healthcare claims-based Lyme disease case-finding algorithms in the United States: A systematic literature review
- Author
-
Young Hee Nam, Sarah J. Willis, Aaron B. Mendelsohn, Susan Forrow, Bradford D. Gessner, James H. Stark, Jeffrey S. Brown, and Sarah Pugh
- Subjects
Lyme Disease ,Insurance Claim Review ,Multidisciplinary ,Databases, Factual ,International Classification of Diseases ,Humans ,Delivery of Health Care ,Algorithms - Abstract
Background and objective Lyme disease (LD) is the fifth most commonly reported notifiable infectious disease in the United States (US) with approximately 35,000 cases reported in 2019 via public health surveillance. However, healthcare claims-based studies estimate that the number of LD cases is >10 times larger than reported through surveillance. To assess the burden of LD using healthcare claims data and the effectiveness of interventions for LD prevention and treatment, it is important to use validated well-performing LD case-finding algorithms (“LD algorithms”). We conducted a systematic literature review to identify LD algorithms used with US healthcare claims data and their validation status. Methods We searched PubMed and Embase for articles published in English since January 1, 2000 (search date: February 20, 2021), using the following search terms: (1) “Lyme disease”; and (2) “claim*” or “administrative* data”; and (3) “United States” or “the US*”. We then reviewed the titles, abstracts, full texts, and bibliographies of the articles to select eligible articles, i.e., those describing LD algorithms used with US healthcare claims data. Results We identified 15 eligible articles. Of these, seven studies used LD algorithms with LD diagnosis codes only, four studies used LD diagnosis codes and antibiotic dispensing records, and the remaining four studies used serologic test order codes in combination with LD diagnosis codes and antibiotics records. Only one of the studies that provided data on algorithm performance: sensitivity 50% and positive predictive value 5%, and this was based on Lyme disease diagnosis code only. Conclusions US claims-based LD case-finding algorithms have used diverse strategies. Only one algorithm was validated, and its performance was poor. Further studies are warranted to assess performance for different algorithm designs and inform efforts to better assess the true burden of LD.
- Published
- 2021
42. Association Between Serious Hypoglycemia and Calcium-Channel Blockers Used Concomitantly With Insulin Secretagogues
- Author
-
Colleen M. Brensinger, Warren B. Bilker, Sean Hennessy, James H. Flory, Young Hee Nam, and Charles E. Leonard
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Hypoglycemia ,Insurance Claim Review ,Diabetes mellitus ,Internal medicine ,Insulin, Regular, Human ,Research Letter ,Medicine ,Humans ,Hypoglycemic Agents ,Drug Interactions ,health care economics and organizations ,Aged ,business.industry ,Calcium channel ,Insulin ,Research ,Secretagogues ,nutritional and metabolic diseases ,General Medicine ,Middle Aged ,medicine.disease ,Calcium Channel Blockers ,United States ,Online Only ,Diabetes and Endocrinology ,Endocrinology ,Diabetes Mellitus, Type 2 ,Female ,business - Abstract
This cohort study investigates whether serious hypoglycemia is reduced in a Medicaid population receiving calcium-channel blockers with insulin secretagogues.
- Published
- 2021
43. Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia
- Author
-
Warren B. Bilker, James H. Flory, Charles E. Leonard, Colleen M. Brensinger, Young Hee Nam, and Sean Hennessy
- Subjects
Male ,medicine.medical_specialty ,Databases, Factual ,medicine.medical_treatment ,Angiotensin-Converting Enzyme Inhibitors ,Nateglinide ,Hypoglycemia ,Article ,Piperidines ,Internal medicine ,Glyburide ,medicine ,Humans ,Hypoglycemic Agents ,Insulin ,Pharmacology (medical) ,Drug Interactions ,Adverse effect ,Aged ,Pharmacology ,Aged, 80 and over ,business.industry ,Medicaid ,Pharmacoepidemiology ,Secretagogues ,Middle Aged ,medicine.disease ,Repaglinide ,Metformin ,United States ,Glimepiride ,Sulfonylurea Compounds ,Diabetes Mellitus, Type 2 ,Female ,Carbamates ,business ,Administrative Claims, Healthcare ,Glipizide ,medicine.drug - Abstract
Serious hypoglycemia is a major adverse event associated with insulin secretagogues. Previous studies have suggested a potential relationship between angiotensin-converting enzyme inhibitors (ACEIs) used with sulfonylureas and serious hypoglycemia, and widely used drug compendia warn of this potential drug-drug interaction. We investigated the association between serious hypoglycemia and concomitant use of ACEIs in patients receiving insulin secretagogues, using the self-controlled case series design and Medicaid claims data from 5 US states linked to Medicare claims from 1999-2011. The exposure of interest was active prescription for ACEIs during insulin secretagogue or metformin (negative control object drug) episodes. The outcome was hospital presentation for serious hypoglycemia, identified by discharge diagnosis codes in inpatient and emergency department claims (positive predictive value ~78-89%). We calculated confounder-adjusted rate ratios (RRs) and 95% confidence internals (CIs) of outcome occurrence during ACEI-exposed versus ACEI-unexposed time using conditional Poisson regression. The RRs for ACEIs were not statistically elevated during observation time of glipizide (RR, 1.06; CI, 0.98-1.15), glyburide (RR, 1.05; CI, 0.96-1.15), repaglinide (RR, 1.15; CI, 0.94-1.41), or metformin (RR, 1.02; CI, 0.97-1.06); but was modestly elevated with glimepiride (RR, 1.23; CI, 1.11-1.37) and modestly reduced with nateglinide (RR, 0.73; CI, 0.56-0.96). The overall pattern of results do not suggest that ACEIs used with insulin secretagogues were associated with increased rates of serious hypoglycemia, with the possible exception of glimepiride.
- Published
- 2021
44. Risk factors of beta-lactam anaphylaxis in Korea: A 6-year multicenter retrospective adult case-control study
- Author
-
Chan Sun Park, Hye Ryun Kang, Jae-Woo Jung, Min Suk Yang, Young-Hee Nam, Hye Jung Park, So Young Park, Dong-Yoon Kang, Sujeong Kim, and Hye-Kyung Park
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Immunology ,Drug allergy ,Cephalosporin ,Case-control studies ,Article ,Food allergy ,Internal medicine ,Ampicillin ,Angiotensin-converting enzyme inhibitors ,medicine ,Immunology and Allergy ,Beta-lactams ,Anaphylaxis ,business.industry ,Case-control study ,Odds ratio ,RC581-607 ,medicine.disease ,Penicillin ,Ceftriaxone ,Immunologic diseases. Allergy ,business ,medicine.drug ,Drug hypersensitivity - Abstract
Background Beta-lactams (BLs) are commonly used antibiotics and leading causative agents of drug-induced anaphylaxis. Few studies on the culprit drugs and risk factors of BL-induced anaphylaxis are available. Our goal was to evaluate the culprit drugs and compare the risk factors in patients with BL-induced anaphylaxis to matched tolerant controls in a hospital setting. Methods We retrospectively enrolled all patients who developed anaphylaxis from intravenous BL during hospitalization from 9 Korean hospitals. We compared clinical parameters between patients with BL-induced anaphylaxis and 4-fold BL-tolerant controls matched by age, sex, BL use, and the purpose of BL administration. Results Seventy-four cases of BL-induced anaphylaxis and 296 BL-tolerant controls were enrolled. Cephalosporin accounted for 77% of total BL-induced anaphylaxis, and the top derivatives were ceftriaxone (23.0%), cefazedone (10.8%), and cefbuperazone (9.5%). Among penicillin derivatives, piperacillin (16.2%) was the most common, followed by ampicillin (2.7%). History of drug allergy (odds ratio [OR], 19.91; 95% confidence interval [CI] 5.33–74.44), previous exposure to the causative BL (OR, 7.71; 95% CI, 1.62–36.76), and concurrent administration of angiotensin-converting enzyme inhibitors (ACEIs) (OR, 5.97; 95% CI, 1.28–27.91) were independent risk factors associated with BL-induced anaphylaxis. Food allergy (OR, 13.93; 95% CI 1.31–148.9) and previous exposure to BL (OR, 6.59; 95% CI, 1.30–33.31) were identified as risk factors for cephalosporin-induced anaphylaxis. Conclusions To prevent BL-induced anaphylaxis, attention should be paid to histories of drug or food allergy, previous exposure to BLs, and ACEI use. The risk factors and clinical outcomes might vary according to the BL classes.
- Published
- 2021
45. Obesity Factors (Physical Activity and Usual Dietary Pattern) and Breast Cancer in Korea
- Author
-
Young-Hee Nam and Myeong Seong Kim
- Subjects
Oncology ,medicine.medical_specialty ,obesity ,Physical activity ,Physical Therapy, Sports Therapy and Rehabilitation ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,breast cancer ,Internal medicine ,met ,medicine ,Orthopedics and Sports Medicine ,030212 general & internal medicine ,business.industry ,Public health ,Dietary pattern ,medicine.disease ,Obesity ,ffq ,030220 oncology & carcinogenesis ,Tourism, Leisure and Hospitality Management ,GV557-1198.995 ,business ,diet ,Sports - Abstract
Introduction. This study sought to evaluate the association between obesity factors (food consumption and physical activity) and breast cancer incidence in Korean women. Material and methods. The study included breast cancer patients (250 women) and normal participants undergoing medical checkups (250 women) who visited a specialized cancer research hospital between August 1, 2016 and February 15, 2017. Nutrient intake was assessed using a validated food frequency questionnaire (FFQ) covering 112 dishes and foods that Koreans often eat. Physical activity was assessed according to the International Physical Activity Questionnaire (IPAQ) guidelines and was quantified as metabolic equivalent (MET) scores. Results. The results for nutrient intake obtained using the FFQ showed that the control group had a higher consumption of dietary fiber (p < 0.004) and a lower intake of animal fat (p < 0.02) than the breast cancer group. Among breast cancer patients, pre-menopausal women consumed more animal fat (18.6 g ± 11.9 vs. 14.7 g ± 8.5, p < 0.03) than post-menopausal ones. An analysis of the MET scores with logistic regression revealed that lower physical activity among cancer patients was associated with an increased risk of breast cancer, and this association was greater among post-menopausal (OR = 2.11, p < 0.001) than pre-menopausal women (OR = 0.85, p < 0.02). Conclusion. Having a high-fat diet and doing less exercise increases the risk of breast cancer, so it is important to prevent the accumulation of fat and maintain proper weight through regular physical activity to lower the incidence of breast cancer.
- Published
- 2019
46. Determinants analysis of affecting to Health screening among Persons with Disabilities
- Author
-
Seon-Yong Kim, YeSoon Kim, and Young-Hee Nam
- Subjects
business.industry ,Environmental health ,Medicine ,business ,Health screening - Published
- 2019
47. Clopidogrel Drug Interactions and Serious Bleeding: Generating Real‐World Evidence via Automated High‐Throughput Pharmacoepidemiologic Screening
- Author
-
Samantha E. Soprano, Young Hee Nam, Warren B. Bilker, Meijia Zhou, Jordana B. Cohen, Sean Hennessy, Charles E. Leonard, Colleen M. Brensinger, and Thanh Phuong Pham Nguyen
- Subjects
Male ,Drug ,medicine.medical_specialty ,Gastrointestinal bleeding ,Databases, Factual ,media_common.quotation_subject ,Population ,Real world evidence ,030226 pharmacology & pharmacy ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Pharmacovigilance ,medicine ,Humans ,Drug Interactions ,Pharmacology (medical) ,education ,Aged ,media_common ,Aged, 80 and over ,Pharmacology ,education.field_of_study ,business.industry ,Pharmacoepidemiology ,Middle Aged ,Clopidogrel ,medicine.disease ,030220 oncology & carcinogenesis ,Female ,Gastrointestinal Hemorrhage ,business ,Intracranial Hemorrhages ,Platelet Aggregation Inhibitors ,Pravastatin ,medicine.drug - Abstract
Few population-based studies have examined bleeding associated with clopidogrel drug-drug interactions (DDIs). We sought to identify precipitant drugs taken concomitantly with clopidogrel (an object drug) that increased serious bleeding rates. We screened 2000-2015 Optum commercial health insurance claims to identify DDI signals. We performed self-controlled case series studies for clopidogrel plus precipitant pairs, examining associations with gastrointestinal bleeding or intracranial hemorrhage. To distinguish native bleeding effects of a precipitant, we reexamined associations using pravastatin as a negative control object drug. Among 431 analyses, 28 clopidogrel plus precipitant pairs were statistically significantly positively associated with serious bleeding. Ratios of rate ratios ranged from 1.13-3.94. Among these pairs, 13 were expected given precipitant drugs alone increased and/or were harbingers of serious bleeding. The remaining 15 pairs constituted new DDI signals, none of which are currently listed in two major DDI knowledge bases.
- Published
- 2019
48. 1200. Healthcare Claims-Based Lyme Disease Case-Finding Algorithms in the United States: A Systematic Literature Review
- Author
-
Young Hee Nam, Sarah J Willis, Aaron Mendelsohn, Susan Forrow, Jeffrey Brown, Bradford D Gessner, James Stark, and Sarah Pugh
- Subjects
Infectious Diseases ,Oncology - Abstract
Background Lyme disease (LD) is the fifth most common notifiable disease in the US with 30,000-40,000 LD cases reported annually via public health surveillance. Recent healthcare claims-based studies utilizing case-finding algorithms estimate national LD cases are >10-fold higher than reported by surveillance. The reliability of claims-based data depends on the accuracy of the case-finding algorithms using the information available in the claims primarily generated for the administrative purposes. To assess the true burden of LD, it is imperative to use validated well-performing LD case-finding algorithms (“LD algorithms”). We conducted a systematic literature review to identify LD algorithms based upon healthcare claims data in the US and their respective performance. Methods We searched PubMed and Embase for articles published in English from January 1, 2000 through the most recent date as of February 20, 2021. We selected articles including all of the following search terms: (1) “Lyme disease”; (2) “claim*” or “administrative* data”; and (3) “United States” or “the US*”. We then reviewed the titles, abstracts, and full texts to identify articles describing LD algorithms developed for claims data. Figure 1 shows the flow diagram following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Results We found 15 articles meeting the inclusion criteria. Of these, 7 study algorithms used only LD diagnosis codes (ICD-9, 088.81; ICD-10, A69.2 or A69.2x), 4 studies additionally used antibiotic dispensing records, and 4 studies additionally used serologic test order codes (CPT 86617, 86618). Three studies used different algorithms for inpatient and outpatient settings. Only one study (in Tennessee, a low-incidence state for LD) provided validation results for their algorithm, which only used a LD diagnosis code (ICD-9, 088.81), with reported sensitivity=50% and positive predictive value=5%. Conclusion Validation data on the LD algorithms developed for healthcare claims data are limited, and suggest algorithms using only LD diagnosis codes may not perform well. Further validation of high-performance claims-based LD algorithms is critical to inform the true burden of LD overall and within subgroups. Disclosures Bradford D. Gessner, MD, MPH, Pfizer Inc. (Employee) James Stark, PhD, Pfizer Inc. (Employee) Sarah Pugh, PhD, Pfizer Inc. (Employee)
- Published
- 2021
49. Phenotypes of Severe Cutaneous Adverse Reactions Caused by Nonsteroidal Anti-inflammatory Drugs
- Author
-
Young Min Ye, Joo-Hee Kim, Min Seok Yang, Min Gyu Kang, Young Il Koh, Sujeong Kim, Jun Gyu Lee, Hyen Oh La, Sae Hoon Kim, Suh Young Lee, Jae Woo Jung, Min Hye Kim, Yi Yeong Jeong, Seong Ju Park, Hye Ryun Kang, Chan Sun Park, Jung Won Park, Gyu Young Hur, Sang-Heon Kim, Hye-Kyung Park, Yong Eun Kwon, Sang Hyon Kim, Young Koo Jee, Young-Hee Nam, Jin Yong Lee, Hyun Jung Jin, Mi Yeong Kim, and Cheol Woo Kim
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,medicine.drug_class ,Immunology ,Scars ,Anti-inflammatory ,Drug Hypersensitivity ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,medicine ,Immunology and Allergy ,030223 otorhinolaryngology ,Adverse effect ,Prospective cohort study ,business.industry ,Anti-Inflammatory Agents, Non-Steroidal ,Overlap syndrome ,medicine.disease ,Dermatology ,Toxic epidermal necrolysis ,Acetaminophen ,stomatognathic diseases ,030228 respiratory system ,Stevens-Johnson Syndrome ,Original Article ,medicine.symptom ,business ,medicine.drug - Abstract
Purpose Nonsteroidal anti-inflammatory drugs (NSAIDs) are common cause of severe cutaneous adverse reactions (SCARs). The present study aimed to investigate the characteristics of SCARs induced by NSAIDs in the Korean SCAR registry. Methods A retrospective survey of NSAID-induced SCARs recorded between 2010 and 2015 at 27 university hospitals in Korea was conducted. Clinical phenotypes of SCARs were classified into Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), SJS-TEN overlap syndrome and drug reaction with eosinophilia and systemic symptoms (DRESS). Causative NSAIDs were classified into 7 groups according to their chemical properties: acetaminophen, and propionic, acetic, salicylic, fenamic and enolic acids. Results A total of 170 SCARs, consisting of 85 SJS, 32 TEN, 17 SJS-TEN overlap syndrome and 36 DRESS reactions, were induced by NSAIDs: propionic acids (n=68), acetaminophen (n=38), acetic acids (n=23), salicylic acids (n=16), coxibs (n=8), fenamic acids (n=7), enolic acids (n=5) and unclassified (n=5). Acetic acids (22%) and coxibs (14%) accounted for higher portions of DRESS than other SCARs. The phenotypes of SCARs induced by both propionic and salicylic acids were similar (SJS, TEN and DRESS, in order). Acetaminophen was primarily associated with SJS (27%) and was less involved in TEN (10%). DRESS occurred more readily among subjects experiencing coxib-induced SCARs than other NSAID-induced SCARs (62.5% vs. 19.7%, P = 0.013). The mean time to symptom onset was longer in DRESS than in SJS or TEN (19.1 ± 4.1 vs. 6.8 ±1.5 vs. 12.1 ± 3.8 days). SCARs caused by propionic salicylic acids showed longer latency, whereas acetaminophen- and acetic acid-induced SCARs appeared within shorter intervals. Conclusions The present study indicates that the phenotypes of SCARs may differ according to the chemical classifications of NSAIDs. To establish the mechanisms and incidences of NSAID-induced SCARs, further prospective studies are needed.
- Published
- 2018
50. Relationship between olfactory and cognitive function in asthma
- Author
-
Hyo-In Rhyou, Young-Hee Nam, and Woo Yong Bae
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,Male ,business.industry ,Immunology ,Cognition ,Olfaction ,Middle Aged ,medicine.disease ,Asthma ,Smell ,Olfaction Disorders ,Immunology and Allergy ,Medicine ,Humans ,Female ,business ,Clinical psychology ,Aged - Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.